Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.
Analysis shows that 65% of patients who took the treatment were alive at 12 months compared to the 11% of patients that did not.
"One-year survival data is an important milestone in any cancer trial, and we are highly encouraged by the meaningful extension of life experienced by patients who benefited from bexmarilimab monotherapy. These data, along with the biomarker data we previously reported, are helping us design our upcoming registrational trials and further support our belief that bexmarilimab monotherapy can increase survival in patients with a variety of late-stage solid tumors," said Chief Medical Officer Marie-Louise Fjallskog.
Current stock price: 220.00 pence, up 3.5% on Wednesday.
12-month change: down 44%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)